The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases

Bibliography

• Carter JR, Ding Z, Rose BR. HPV infection and cervical disease: a review. Aust N Z J Obstet Gynaecol 2011;51(2):103–8
   PubMed Web of Science ®Google Scholar
• Paavonen J. Human papillomavirus infection and the development of cervical cancer and related genital neoplasias. Int J Infect Dis 2007;11(Suppl 2):S3–9
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61(2):69–90
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356(19):1928–43
   PubMed Web of Science ®Google Scholar
• Balofsky A, Agmon-Levin N, Shoenfeld Y. The new H1N1 and HPV vaccines and old fears. Curr Opin Rheumatol 2010;22(4):431–6
   PubMed Web of Science ®Google Scholar
• Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001;93(4):284–92
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364(9447):1757–65
   PubMed Web of Science ®Google Scholar
• Tomljenovic L, Shaw CA. Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds? Ann Med 2013;45(2):182–93
   PubMed Web of Science ®Google Scholar
• Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369(9576):1861–8
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RLR, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95(11):1459–66
   PubMed Web of Science ®Google Scholar
• De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010;28(38):6247–55
   PubMed Web of Science ®Google Scholar
• Harper DM, Williams KB. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discov Med 2010;10(50):7–17
   PubMedGoogle Scholar
• Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother 2014;10(8):2147–62
   PubMed Web of Science ®Google Scholar
• Castle PE. Beyond human papillomavirus: the cervix, exogenous secondary factors, and the development of cervical precancer and cancer. J Low Genit Tract Dis 2004;8(3):224–30
   PubMedGoogle Scholar
• Vaccine safety [Internet]. Available from: http://www.who.int/vaccine_safety/en/ [Last accessed 25 April 2015]
   Google Scholar
• Possible side-effects of vaccines. Internet Available from: http://www.cdc.gov/vaccines/vac-gen/side-effects.htm [Last accessed 25 April 2015]
   Google Scholar
• Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity-‘vaccinosis’: a dangerous liaison? J Autoimmun 2000;14(1):1–10
   PubMed Web of Science ®Google Scholar
• Agmon-Levin N, Paz Z, Israeli E, et al. Vaccines and autoimmunity. Nat Rev Rheumatol 2009;5(11):648–52
   PubMed Web of Science ®Google Scholar
• Israeli E, Agmon-Levin N, Blank M, et al. Guillain-Barré syndrome--a classical autoimmune disease triggered by infection or vaccination. Clin Rev Allergy Immunol 2012;42(2):121–30
   PubMed Web of Science ®Google Scholar
• Tomljenovic L, Shaw CA. Adverse reactions to human papillomavirus (HPV) vaccines. In: Shoenfeld Y, Agmon-Levin N, Tomljenovic L, editors. 1st edition. Wiley Press; New York: 2015
   Google Scholar
• Shoenfeld Y, Zandman-Goddard G, Stojanovich L, et al. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases--2008. Isr Med Assoc J 2008;10(1):8–12
   PubMed Web of Science ®Google Scholar
• Soriano A, Nesher G, Shoenfeld Y. Predicting post-vaccination autoimmunity: who might be at risk? Pharmacol Res 2015;92:18–22
   Google Scholar
• Feenstra B, Pasternak B, Geller F, et al. Common variants associated with general and MMR vaccine-related febrile seizures. Nat Genet 2014;46(12):1274–82
   PubMed Web of Science ®Google Scholar
• Pellegrino P, Falvella FS, Perrone V, et al. The first steps towards the era of personalised vaccinology: predicting adverse reactions. Pharmacogenomics J 2015;15(3):284–7
   PubMed Web of Science ®Google Scholar
• Zivkovic I, Petrusic V, Stojanovic M, et al. Induction of decreased fecundity by tetanus toxoid hyper-immunization in C57BL/6 mice depends on the applied adjuvant. Innate Immun 2012;18(2):333–42
   PubMed Web of Science ®Google Scholar
• Israeli E, Agmon-Levin N, Blank M, et al. Adjuvants and autoimmunity. Lupus 2009;18(13):1217–25
   PubMed Web of Science ®Google Scholar
• Safranek TJ, Lawrence DN, Kurland LT, et al. Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group. Am J Epidemiol 1991;133(9):940–51
   PubMed Web of Science ®Google Scholar
• Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National influenza immunization program, United States, 1976--1977. Am J Epidemiol 1979;110(2):105–23
   PubMed Web of Science ®Google Scholar
• Orbach H, Agmon-Levin N, Zandman-Goddard G. Vaccines and autoimmune diseases of the adult. Discov Med 2010;9(45):90–7
   PubMed Web of Science ®Google Scholar
• Zafrir Y, Agmon-Levin N, Paz Z, et al. Autoimmunity following hepatitis B vaccine as part of the spectrum of “Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants” (ASIA): analysis of 93 cases. Lupus 2012;21(2):146–52
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Agmon-Levin N. “ASIA” - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011;36(1):4–8
   PubMed Web of Science ®Google Scholar
• Vera-Lastra O, Medina G, Cruz-Dominguez MDP, et al. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld’s syndrome): clinical and immunological spectrum. Expert Rev Clin Immunol 2013;9(4):361–73
   PubMed Web of Science ®Google Scholar
• Agmon-Levin N, Hughes GR V, Shoenfeld Y. The spectrum of ASIA: “Autoimmune (Auto-inflammatory) syndrome induced by adjuvants”. Lupus 2012;21(2):118–20
   PubMed Web of Science ®Google Scholar
• Perricone C, Agmon-Levin N, Shoenfeld Y. Novel pebbles in the mosaic of autoimmunity. BMC Med 2013;11:101
   PubMed Web of Science ®Google Scholar
• Gatto M, Agmon-Levin N, Soriano A, et al. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol 2013;32(9):1301–7
   PubMed Web of Science ®Google Scholar
• McCarthy JE, Filiano J. Opsoclonus Myoclonus after human papilloma virus vaccine in a pediatric patient. Parkinsonism Relat Disord 2009;15(10):792–4
   PubMed Web of Science ®Google Scholar
• Karussis D, Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev 2014;13(3):215–24
   PubMed Web of Science ®Google Scholar
• Agorastos T, Chatzigeorgiou K, Brotherton JML, et al. Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. Vaccine 2009;27(52):7270–81
   PubMed Web of Science ®Google Scholar
• Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302(7):750–7
   PubMed Web of Science ®Google Scholar
• Macartney KK, Chiu C, Georgousakis M, et al. Safety of human papillomavirus vaccines: a review. Drug Saf 2013;36(6):393–412
   PubMed Web of Science ®Google Scholar
• Block SL, Brown DR, Chatterjee A, et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Pediatr Infect Dis J 2010;29(2):95–101
   PubMed Web of Science ®Google Scholar
• Labadie J. Postlicensure safety evaluation of human papilloma virus vaccines. Int J Risk Saf Med 2011;23(2):103–12
   PubMedGoogle Scholar
• Stillo M, Carrillo Santisteve P, Lopalco PL. Safety of human papillomavirus vaccines: a review. Expert Opin Drug Saf 2015;14(5):1–16
   PubMed Web of Science ®Google Scholar
• World Health Organization. Vaccine safety. Internet Available from: http://www.who.int/vaccine_safety/committee/topics/hpv/GACVS_Statement_HP V_12_Mar_2014.pdf?ua=1 [Last accessed 3 June 2015]
   Google Scholar
• World Health Organization. Weekly epidemiological record. Available from: http://www.who.int/wer/2014/wer8943.pdf?ua=1
   Google Scholar
• Souayah N, Michas-Martin PA, Nasar A, et al. Guillain-Barré syndrome after Gardasil vaccination: data from vaccine adverse event reporting system 2006-2009. Vaccine 2011;29(5):886–9
   PubMed Web of Science ®Google Scholar
• Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 2012;271(2):193–203
   PubMed Web of Science ®Google Scholar
• Slade BA, Gee J, Broder KR, et al. Comment on the contribution by Souayah et al., “Guillain-Barré syndrome after Gardasil vaccination: data from vaccine adverse event reporting system 2006-2009”. Vaccine 2011;29(5):865–6
   PubMed Web of Science ®Google Scholar
• Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the vaccine safety datalink. Vaccine 2011;29(46):8279–84
   PubMed Web of Science ®Google Scholar
• Thieben MJ, Sandroni P, Sletten DM, et al. Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc 2007;82(3):308–13
   PubMed Web of Science ®Google Scholar
• Blitshteyn S. Postural tachycardia syndrome after vaccination with Gardasil. Eur J Neurol 2010;17(7):e52
   Google Scholar
• Blitshteyn S. Postural tachycardia syndrome following human papillomavirus vaccination. Eur J Neurol 2014;21(1):135–9
   PubMed Web of Science ®Google Scholar
• Brinth L, Theibel AC, Pors K, et al. Suspected side effects to the quadrivalent human papilloma vaccine. Dan Med J 2015;62(4):A5064
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Abe R-T, Hineno A, et al. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med 2014;53(19):2185–200
   PubMed Web of Science ®Google Scholar
• Baker VL. Primary ovarian insufficiency in the adolescent. Curr Opin Obstet Gynecol 2013;25(5):375–81
   PubMed Web of Science ®Google Scholar
• Little DT, Ward HRG. Adolescent premature ovarian insufficiency following human papillomavirus vaccination: a case series seen in general practice. J Investig Med High Impact Case Reports 2014;2:4
   Google Scholar
• Klein NP, Hansen J, Chao C, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med 2012;166(12):1140–8
   PubMed Web of Science ®Google Scholar
• Arnheim-Dahlström L, Pasternak B, Svanström H, et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013;347:f5906
   PubMed Web of Science ®Google Scholar
• VAERS data [Internet]. Available from: https://vaers.hhs.gov/data/index [Last accessed 25 April 2015]
   Google Scholar
• Geier DA, Geier MR. A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events. Clin Rheumatol 2015;34(7):1225–31
   PubMed Web of Science ®Google Scholar
• Soldevilla HF, Briones SFR, Navarra S V. Systemic lupus erythematosus following HPV immunization or infection? Lupus 2012;21(2):158–61
   PubMed Web of Science ®Google Scholar
• Soybilgic A, Onel KB, Utset T, et al. Safety and immunogenicity of the quadrivalent HPV vaccine in female systemic lupus erythematosus patients aged 12 to 26 years. Pediatr Rheumatol Online J 2013;11:29
   PubMed Web of Science ®Google Scholar
• Pellegrino P, Perrone V, Pozzi M, et al. The epidemiological profile of ASIA syndrome after HPV vaccination: an evaluation based on the vaccine adverse event reporting systems. Immunol Res 2015;61(1-2):90–6
   PubMed Web of Science ®Google Scholar
• Natale C, Giannini T, Lucchese A, et al. Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences. Immunol Cell Biol 2000;78(6):580–5
   PubMed Web of Science ®Google Scholar
• Bayas J-M, Costas L, Muñoz A. Cervical cancer vaccination indications, efficacy, and side effects. Gynecol Oncol 2008;110(3 Suppl 2):S11–14
   Google Scholar
• Hem SL. Elimination of aluminum adjuvants. Vaccine 2002;20(Suppl 3):S40–3
   PubMedGoogle Scholar
• Lee SH. Detection of human papillomavirus (HPV) L1 gene DNA possibly bound to particulate aluminum adjuvant in the HPV vaccine Gardasil. J Inorg Biochem 2012;117:85–92
   PubMed Web of Science ®Google Scholar
• Lee S. Detection of human papillomavirus L1 gene DNA fragments in postmortem blood and spleen after GardasilReg. vaccination - a case report. Adv Biosci Biotechnol 2012;3(8):1214–24
   Google Scholar